Tijdens de mazelenopleving van 2025 als volwassene een BMR (MMR)-titerbepaling of boosterprik laten doen, of overslaan?
Als je handelt
Een BMR-titer of boosterdosis als volwassene halen
0,001%
Als je niets doet
De titer/booster overslaan en vertrouwen op aangenomen kinderimmuniteit
6,0%
Percentage dat later spijt heeft van elke keuze. De balken en het volledige overzicht staan hieronder.
Gezondheid
Laatst beoordeeld 2026-06-13
Kwaliteit van bewijs 4.1/5
Beoordelingsscore op acht dimensies volgens de
kwaliteitsrubriek
. Elke dimensie krijgt een score van 1 tot 5.
D1 Bronverificatie
5/5
D2 Autoriteit en onafhankelijkheid van bronnen
5/5
D3 Nauwkeurigheid van spijtcijfer
3/5
D4 Vergelijkbaarheid van bronnen
3/5
D5 Gilovich-patroon
4/5
D6 Prozakwaliteit
4/5
D7 Volledigheid van voorbehouden
4/5
D8 Steekproefkwaliteit
5/5
Gemiddelde4.1/5
Proxygegevens — er bestaat geen directe spijtenquête voor deze beslissing. De percentages zijn afgeleid van tevredenheidsscores en toegangsdrempelgegevens in plaats van vragen die direct naar spijt vroegen. Zie opmerkingen hieronder.
Spijt van handelen
Een BMR-titer of boosterdosis als volwassene halen
0,001%
<0.001% — proxy: a serious adverse event (anaphylaxis) is the only material downside; redundancy in an already-immune adult is not a regret-worthy outcome
US adults who seek an MMR titer or a precautionary MMR dose (1963-67 killed-vaccine cohort, healthcare personnel, immunocompromised contacts) during the 2025 resurgence
Per dose administered
Spijt van nalaten
De titer/booster overslaan en vertrouwen op aangenomen kinderimmuniteit
6,0%
~6% — proxy: share of a US healthcare-worker serosurvey lacking a measles immunity marker (seronegative + equivocal); an upper bound on who carries an immunity gap, not a measured regret rate
US adults in the named higher-risk cohorts (1963-67 killed-vaccine recipients, healthcare personnel, immunocompromised) who skip serologic check or revaccination during the 2025 resurgence
Cross-sectional immunity gap during the 2025 resurgence
% betreurt deze keuze
Een BMR-titer of boosterdosis als volwassene halenDe titer/booster overslaan en vertrouwen op aangenomen kinderimmuniteit
0,001%6,0%
inaction dominates — Niets doen domineert — de meesten hebben spijt dat ze niet handelden.
Gerelateerde keuzes
Semantisch vergelijkbare keuzes — zelfde terrein, andere afwegingen.
Aanbevolen volwassenenvaccinaties overslaan of weigeren (geen jaarlijkse griepprik, geen COVID-boosters, geen gordelroosvaccin vanaf 50, geen HPV-inhaalvaccinatie)Het aanbevolen vaccinatieschema voor volwassenen volgen (jaarlijkse griep, COVID-19-boosters, gordelroos vanaf 50, HPV-inhaalvaccinatie tot 45)
Aanbevolen reisvaccinaties overslaan of weigeren (geen hep A of tyfus vóór Zuid-/Zuidoost-Azië, geen gele koorts vóór endemisch Afrika of Zuid-Amerika, geen Japanse encefalitis voor landelijk Azië)De aanbevolen reisvaccinaties halen volgens de CDC/WHO-bestemmingsrichtlijnen vóór vertrek (hep A en tyfus voor niet-westerse bestemmingen, gele koorts voor endemische zones, JE voor verblijven van ≥1 maand in landelijk Azië)
Een door CDC/WHO aanbevolen antimalariachemoprofylaxeschema (atovaquon-proguanil/Malarone, doxycycline of mefloquine) innemen voor, tijdens en na een reis naar een malaria-endemische bestemmingAntimalariachemoprofylaxe overslaan en uitsluitend vertrouwen op preventie tegen muggenbeten (DEET, met permethrine behandelde kleding, ramen met gaas, klamboes) voor een reis naar een malaria-endemische bestemming
De geplande reis uitstellen of annuleren vanwege acute ziekte, recente operatie, zwangerschap met complicaties, immuundeficiëntie of een actieve uitbraak op de bestemmingReizen zoals gepland ondanks acute ziekte, recente operatie, zwangerschapscomplicatie, immuundeficiëntie tijdens een uitbraak op de bestemming of andere waarschuwing uit de luchtvaartgeneeskunde
No survey asks adults whether they regret getting, or skipping, a measles booster during the 2025 resurgence. The few documented post-outbreak interviews run the other way: the parents of the Texas child who died in 2025 told reporters they stood by their decision not to vaccinate. So this pair is a proxy. The action side is anchored on the probability of a serious adverse event from the shot itself, and the inaction side on the share of the relevant cohort that carries no measurable measles immunity. Neither number is a regret rate; both are stand-ins, and the gap between them is wide.
The action downside is small and well-characterized. Anaphylaxis after an MMR-containing vaccine was reported to VAERS at 0.6 per million doses over 1990 to 2016, and the CDC’s Vaccine Information Statement describes a serious reaction as a “very remote chance.” The common outcomes — a sore arm, a brief fever, a mild rash — are not the kind of thing people later regret. The subtler point is that for the large majority of adults who turn out to have been immune already, the booster was redundant rather than harmful, and a redundant-but-protective dose tends to read as reassurance, not as a mistake. That is why the action proxy sits near the floor: the only genuinely regret-worthy action outcome is the rare serious event, on the order of one in a hundred thousand or rarer.
The inaction side is where the cohorts in the question matter. A US healthcare-worker serosurvey found 4% seronegative and 2% equivocal for measles IgG — a roughly 6% immunity gap — and a 2025 meta-analysis of 23,236 vaccinated people pooled seropositivity at 87.8%, falling to 84.3% among single-dose recipients. The 1963-67 killed-vaccine cohort is a separate, smaller group that ACIP explicitly tells to revaccinate, because the inactivated product conferred little durable protection. The catch is that an immunity gap is not the same as realized regret: with 2,288 confirmed US cases in 2025 against a population of roughly 340 million, the national attack rate stayed near 0.0007%, so most seronegative adults were never exposed at all. What gives the gap its weight is the severity tail — 11% of 2025 cases were hospitalized and there were deaths — so the rare intersection of “no immunity” and “exposed” is consequential. The honest reading: skipping leaves a measurable hole in protection for a minority of these cohorts, getting the dose closes it at trivial cost, and the realized-regret asymmetry favors acting even though almost no one in either group will ever face the outcome that would make the choice matter.
Bronnen: handelen
Bronnenverantwoording
Elk getal hieronder is wat elke bron rapporteerde, met het letterlijke citaat waarop we ons baseerden en hoe we tot ons cijfer kwamen. Klik op een link om rechtstreeks te verifiëren.
1/2 bronnen onafhankelijk woordelijk geverifieerd tegenover de geciteerde bron
[1]Journal of Allergy and Clinical Immunology / NCBI PMC — Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990–2016
Geverifieerd
Vakgenoten-beoordeeld
MMR-containing vaccine anaphylaxis reporting rate of 0.6 per 1 million doses distributed (overall vaccine rate 1.3 per million).
Fragment
“The estimated rate of anaphylaxis reported to VAERS during 1990 to 2016 after MMR was 0.6 per 1 million doses distributed.”
Brongegevens van
2019-01-01
Geraadpleegd
2026-06-13
Verificatie
Fragment onafhankelijk opnieuw opgehaald en woord voor woord bevestigd tegenover de geciteerde bron tijdens onze onderbouwingsaudit.
Berekening
Anaphylaxis is the canonical serious adverse event of MMR. 0.6 per 1,000,000 doses = 6e-7. The action regret_rate is set conservatively above that floor (1e-5) to absorb other rare serious events (febrile seizure, transient thrombocytopenia) the VIS lists. The dominant 'downside' of acting for an already-immune adult is a redundant dose, which yields peace of mind rather than regret, so it is not counted as regret. This is the matched-severity proxy: action's regret-worthy outcome is a serious AE, not 'the shot turned out unnecessary'.
[2]U.S. Centers for Disease Control and Prevention — MMR Vaccine Information Statement (VIS)
Overheidsrapport
Serious adverse events from MMR are characterized as a very remote chance; common effects are minor (sore arm, fever, mild rash).
Fragment
“As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.”
Brongegevens van
2025-01-31
Geraadpleegd
2026-06-13
Berekening
Qualitative confirmation that the action side's serious downside is 'very remote.' Establishes that the regret-worthy outcome of acting is rare and severe (an AE), distinct from the common, non-regret outcome of a redundant-but-protective dose. No numeric rate on this page; the numeric anchor is PMC6580415.
Bronnen: niet handelen
Bronnenverantwoording
Elk getal hieronder is wat elke bron rapporteerde, met het letterlijke citaat waarop we ons baseerden en hoe we tot ons cijfer kwamen. Klik op een link om rechtstreeks te verifiëren.
3/6 bronnen onafhankelijk woordelijk geverifieerd tegenover de geciteerde bron
[1]Infection Control and Hospital Epidemiology (PubMed) — Measles immunity in a population of healthcare workers
Geverifieerd
Vakgenoten-beoordeeld
Among 2,473 US healthcare workers tested for anti-measles IgG, 4% were seronegative and 2% equivocal — a ~6% immunity gap.
Fragment
“Ninety-three workers (4%) were seronegative, and 56 (2%) were equivocal.”
Brongegevens van
1994-01-01
Geraadpleegd
2026-06-13
Verificatie
Fragment onafhankelijk opnieuw opgehaald en woord voor woord bevestigd tegenover de geciteerde bron tijdens onze onderbouwingsaudit.
Berekening
Population-matched anchor: US healthcare workers, one of the named higher-risk cohorts. Seronegative (4%) + equivocal (2%) = 6% lacking a measles immunity marker → inaction proxy 0.06. This is an immunity-gap upper bound, not a realized-regret rate: most seronegative people are never exposed (2025 national attack rate ~ 2,288 / ~340M ~ 0.0007%). The proxy measures who is even eligible for potential regret if exposed.
[2]eClinicalMedicine (The Lancet Discovery Science) — Measles seropositivity in previously vaccinated individuals: a systematic review and meta-analysis
Vakgenoten-beoordeeld
Pooled seropositivity among vaccinated individuals was 87.8% (so ~12.2% seronegative); single-dose recipients 84.3% seropositive (~15.7% seronegative), across 23,236 individuals from 10 countries.
Fragment
“Pooled seropositivity was 87·8% (95% CI, 83·9%–91·2%) across 23,236 vaccinated individuals”
Brongegevens van
2025-01-01
Geraadpleegd
2026-06-13
Berekening
Current (2025) pooled anchor confirming waning: ~12% of vaccinated adults are below seropositivity thresholds, rising to ~16% for single-dose recipients. Verified verbatim via Playwright (Lancet 403s WebFetch). Used to frame the spread; the 6% HCW figure is kept as the population-matched headline rather than the 12-16% pooled (mixed-country, assay-threshold) number to avoid overstating realized susceptibility.
[3]U.S. Centers for Disease Control and Prevention — Measles Vaccination for Specific Groups
Overheidsrapport
ACIP recommends revaccinating recipients of killed/inactivated or unknown-type measles vaccine from 1963-1967; healthcare personnel without presumptive immunity need 2 doses.
Fragment
“The ACIP recommends re-vaccinating anyone who received measles vaccine of unknown type, inactivated measles vaccine, or further attenuated measles vaccine accompanied by immunoglobulin or high-titer measles immune globulin (no longer available in the United States) during these years with 1 or 2 doses.”
Brongegevens van
2024-07-15
Geraadpleegd
2026-06-13
Berekening
Establishes that the 1963-67 killed-vaccine cohort is functionally unprotected per ACIP and explicitly advised to revaccinate — the qualitative basis for why skipping carries downside for this cohort. This cohort is <5% of adults and overlaps the pre-1957 presumed-immune group, so it informs but does not set the numeric anchor.
[4]CDC MMWR / NCBI PMC — Measles Update — United States, January 1–April 17, 2025
Geverifieerd
Overheidsrapport
Of 800 confirmed 2025 cases through April 17, 96% were unvaccinated or unknown status, 11% hospitalized, 3 deaths.
Fragment
“Overall, 771 (96%) patients have been unvaccinated or had unknown vaccination status”
Brongegevens van
2025-04-24
Geraadpleegd
2026-06-13
Verificatie
Fragment onafhankelijk opnieuw opgehaald en woord voor woord bevestigd tegenover de geciteerde bron tijdens onze onderbouwingsaudit.
Berekening
Establishes the severity tail that makes the immunity gap consequential: 11% of measles cases hospitalized, 3 deaths in the period, 96% of cases in the unvaccinated/unknown. The realized harm to someone in the immunity gap who is exposed is severe; this is what gives the inaction proxy its weight.
[5]U.S. Centers for Disease Control and Prevention — Measles Cases and Outbreaks — 2025 Data Summary
Geverifieerd
Overheidsrapport
Full-year 2025: 2,288 confirmed US measles cases — the largest annual count since 1992.
Fragment
“For the full year of 2025, a total of 2,288 confirmed* measles cases were reported in the United States.”
Brongegevens van
2026-06-12
Geraadpleegd
2026-06-13
Verificatie
Fragment onafhankelijk opnieuw opgehaald en woord voor woord bevestigd tegenover de geciteerde bron tijdens onze onderbouwingsaudit.
Berekening
Sets the exposure backdrop: 2,288 cases / ~340M US population ~ 0.0007% national attack rate. This is why the 6% immunity-gap proxy is explicitly an upper bound on potential regret, not realized regret — exposure remained geographically concentrated and rare nationally even in the worst year since 1992.
[6]The Texas Tribune — Texas measles victim's parents stand by decision to not vaccinate
Nieuwsartikel
After their unvaccinated 6-year-old daughter died of measles in Gaines County, Texas in February 2025, the parents said in a recorded statement that the death did not change their opposition to the MMR vaccine.
Fragment
“"We would absolutely not take the MMR," the mother said, adding that her stance on vaccination has not changed after her daughter's death.”
Brongegevens van
2025-03-20
Geraadpleegd
2026-07-03
Berekening
Illustrative real-world counterpoint, not a numeric input to the 0.06 inaction proxy: a parent's decision about a child's routine MMR dose amid a measles death is a different population and decision from the adult titer/booster question this entry covers, and one family's account is not a survey. Cited to support the body-text point that documented post-outbreak reactions do not uniformly run toward regretting non-vaccination.
Kanttekeningen
proxy_only: there is no direct "regret getting/skipping an MMR booster" survey; both rates are stand-ins. The inaction rate (6%) is the share of a US healthcare-worker serosurvey lacking an immunity marker (seronegative + equivocal), i.e. an upper bound on who is even eligible for regret, NOT a measured regret rate — most seronegative people are never exposed (2025 national attack rate ~0.0007%). The susceptibility spread is wide and assay-dependent: 6% (US HCW IgG), 12.2% (2025 pooled meta-analysis), up to ~37.6% in one Olmsted County, MN commercial-assay study whose high figure is largely a below-titer-threshold artifact (titer below cutoff does not equal susceptible, because anamnestic memory-B-cell immunity is not captured) and is therefore excluded from the anchor. The 1963-67 killed-vaccine cohort is <5% of adults and overlaps the pre-1957 presumed-immune group, so it is a qualitative ACIP-revaccinate flag rather than the numeric anchor. The action anaphylaxis figure (0.6/million) is a passive-surveillance VAERS reporting rate, not a measured incidence. The meta-analysis pools 10 countries, not US-only. CDC publishes immunity and case data, not regret; this entry should not be read as advice to get or skip a dose.
